UK femtocell vendor Ubiquisys has raised US$5m from three Taiwanese groups in a second funding round.
Vendor SerComm, which is also Ubiquisys’ manufacturing partner, and investment groups UMC Capital and Pacific Venture Partners participated.
According…
UK femtocell vendor Ubiquisys has raised US$5m from three Taiwanese groups in a second funding round.
Vendor SerComm, which is also Ubiquisys’ manufacturing partner, and investment groups UMC Capital and Pacific Venture Partners participated.
According to Ubiquisys, the new fundraising will allow it to capitalise on strategic deals in Asia, such as its partnership with SerComm and its flagship deployment with Japanese mobile operator SoftBank Mobile.
“Asia plays a leading role in the femtocell industry today, both in terms of product diversity and business model innovation,” said Chris Gilbert, CEO at Ubiquisys.
“Our work with SoftBank and SerComm has broken new ground and we are delighted to be adding strategic investors who bring extra know-how to help Ubiquisys build on our strong international momentum.”
Ubiquisys’ first funding round, which completed on July 12, raised US$9m from 5 Continents Consulting Group (5CCG) and Japanese VC Yasuda Enterprise Development. Advent Venture Partners, Accel Partners and Atlas Venture are the existing investors.
At the time, Ubiquisys said the capital would be used to meet demand for its femtocell technology in new markets, such as indoor hot-spots, metro and rural deployments.
Ubiquisys declined to reveal whether it had hired any advisers or when a third round was expected.
